Symptoms and General Pathology

All Conditions

Neoplasms

Nervous System Diseases

Rare Diseases

Recurrence

Glioma

Brain Neoplasms

Disease Progression

Meningioma

Ependymoma

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Antineoplastic Agents

All Drugs and Chemicals

Irinotecan

Bevacizumab

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Topoisomerase I Inhibitors

Enzyme Inhibitors

125 mg/m2 non-EIAED or 340 mg/m2 EIAED every 2 weeks

Ulrik Lassen, MD., PH.D.

Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months. Given the synergy between irinotecan and bevacizumab in colorectal cancer, and the high-level expression of vascular endothelial growth factor on malignant gliomas, one would expect synergy between bevacizumab and irinotecan against gliomas.

Recent data form a small study of 32 patients from Duke University have achieved a response rate of 62% in patients with malignant gliomas. Most included patients had glioblastomas, but this regimen may also have activity in more rare primary malignant brain tumors. The investigators therefore plan to include other primary malignant brain tumors in this study, and the clinical activity will be correlated with biomarkers and PET results of metabolic activity and blood flow. This may result in information that can be used to individualize therapy in the future.

Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy

Rigshospitalet, Denmark

Ulrik Lassen

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy	NCT00463203	Brain Neoplasms Glioma	Bevacizumab Irinotecan	18 Years -	Rigshospitalet, Denmark
Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy	NCT00463203	Brain Neoplasms Glioma	Bevacizumab Irinotecan	18 Years -	Rigshospitalet, Denmark

Spots Global Cancer Trial Database for meningeoma

Every month we try and update this database with for meningeoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for meningeoma

Every month we try and update this database with for meningeoma cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for meningeoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.